All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Key takeaways and updates from SOHO 2023
Featured
Bookmark this article
During the Society of Hematologic Oncology (SOHO) 2023 Congress, the Lymphoma Hub spoke to Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What are the key takeaways and updates from SOHO 2023?
Key takeaways and updates from SOHO 2023
Firstly, Salles discusses the key session on follicular lymphoma (FL) which covered use of the Eastern Cooperative Oncology Group (ECOG) performance status, Follicular Lymphoma International Prognostic Index score, clinical parameters, and biological insights to predict outcomes in patient with FL. He then highlights the available treatments for patients experiencing disease progression within 24 months and the role of bispecific antibodies (mosenutuzumab, odronextamab, epcoritimab, and glofitamab) in FL. He concludes that monitoring patients with FL could help to identify a panel of mutations that explain the differences in response between patients.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youRelated articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox